Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Sarcoma 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lymphoma 1Insulin-Like Growth Factor I, Resistance To 1Colonic Neoplasms 1Carcinoid Tumor 1

Interventions

ganitumab 2conatumumab 1cixutumumab 1Paclitaxel 1Lapatinib 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Insulin-Like Growth Factor I, Resistance To × conatumumab × Clear all
NCT00630552 2024-10-17

QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer

NantCell, Inc.

Phase 1/2 Completed
138 enrolled 19 charts
Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡